A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Vibegron (GEMTESA)

beta3-Adrenergic Agonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2020-12-29
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$1.46B in CY2024 Part D spend2.2M claims · 594K beneficiaries · 329 plans surveyed

Lowest NADAC
$16.47/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$16.47
Across all dosage forms in distribution.
Highest NADAC
$16.47
Range is tight.
Plans with PA
2 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Vibegron used for?

Vibegron is a beta3-Adrenergic Agonist medication tracked in Medicare Part D.

Is there a generic for Vibegron?

No. Vibegron is brand-only with no generic equivalents currently in market.

How much does my plan pay for Vibegron?

Across 329 Part D plans, Vibegron averages $16.47/unit (NADAC). Lowest available: $16.47/unit. Highest in distribution: $16.47/unit.

Is Vibegron on the FDA shortage list?

No. Vibegron is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

beta3-Adrenergic Agonist1 alternative in D1
01
Mirabegron
Brand: Mirabgeorn
$2.21Lowest NADAC
6Generic mfrs
$3.59BCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.